Edition:
United States

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

4,514.00GBp
10:23am EST
Change (% chg)

-105.00p (-2.27%)
Prev Close
4,619.00p
Open
4,594.50p
Day's High
4,618.50p
Day's Low
4,503.00p
Volume
1,120,338
Avg. Vol
2,440,166
52-wk High
5,377.00p
52-wk Low
3,423.00p

SHP.L

Chart for SHP.L

About

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.... (more)

Overall

Beta: 1.45
Market Cap(Mil.): £42,226.34
Shares Outstanding(Mil.): 904.20
Dividend: 3.51
Yield (%): --

Financials

  SHP.L Industry Sector
P/E (TTM): 63.49 29.84 30.76
EPS (TTM): 0.74 -- --
ROI: 1.09 15.39 14.82
ROE: 2.09 16.58 16.24

Shire confident rare drugs will be valued, despite Trump threats

DAVOS, Switzerland Shire, which sells some of the world's most expensive prescription drugs, believes the U.S. market will continue to recognize the value of its rare disease treatments, despite sabre-rattling on pricing by President-elect Donald Trump.

8:18am EST

U.S. says Shire subsidiaries to pay $350 million to settle false claims act allegations

WASHINGTON Shire PLC subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act allegations related to unlawful methods to push “Dermagraft,” a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday.

Jan 11 2017

U.S. says Shire subsidiaries to pay $350 mln to settle false claims act allegations

WASHINGTON, Jan 11 Shire PLC subsidiaries will pay $350 million to settle U.S. federal and state False Claims Act allegations related to unlawful methods to push "Dermagraft," a treatment for diabetic foot ulcers, the U.S. Justice Department said in a statement on Wednesday.

Jan 11 2017

BRIEF-Xenetic Biosciences receives $3 mln milestone payment from Shire Plc

* Xenetic Biosciences receives $3 million milestone payment from Shire Plc for psa-recombinant shp656 in development for long-acting treatment for hemophilia

Jan 06 2017

Momenta's Humira biosimilar succeeds in key psoriasis study

U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

UPDATE 1-Momenta's Humira biosimilar succeeds in key psoriasis study

Nov 29 U.S. biotech Momenta Pharmaceuticals Inc said on Tuesday its experimental biosimilar version of AbbVie Inc's top-selling autoimmune drug, Humira, met the main goal in a late-stage trial involving patients with a form of psoriasis.

Nov 29 2016

Omega's Einhorn sees Trump's policies boosting stocks

NEW YORK U.S. stocks are poised to climb more in 2017 as the policies of Republican President-elect Donald Trump are likely to boost earnings, Steven Einhorn, vice chairman of Hedge fund Omega Advisors, said on Monday.

Nov 15 2016

UPDATE 1-Shire sees opportunity in Asia, aims to double revenue by 2020

* Sees opportunity as China opens consultation on key drugs list

Nov 11 2016

Shire sees opportunity in Asia, aims to double revenue by 2020

SINGAPORE, Nov 11 Shire, a specialist in rare diseases, aims to double Asian sales by 2020, as it targets markets including China, where it hopes to put its haemophilia drugs on a reimbursement list being updated this year for the first time since 2009.

Nov 11 2016

Earnings vs. Estimates